Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon

1 Jan 2008

Abstract excerpt

Coumarin oral anticoagulant drugs have proven to be effective for the prevention of thromboembolic events. World-wide, warfarin is the most prescribed drug. In Europe, acenocoumarol and phenprocoumon are also administered. Yet it has been proven that variant alleles of the VKORC1 and CYP2C9 genotypes influence the pharmacokinetics and pharmacodynamics of these drugs. The combination of these two variant genotypes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmaceutical studies and practices
Share to Pharmacogenetics and Drug Metabolism

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 19132230
DOI: 10.1160/th08-04-0116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumonPMID 19132230Read ↗

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.Semantic proximity Read ↗

An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.Semantic proximity Read ↗

Pharmacogenetics of Oral Anticoagulant TherapySemantic proximity Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

The future prospects of pharmacogenetics in oral anticoagulation therapySemantic proximity Read ↗

Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing.Semantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.Semantic proximity Read ↗

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?Semantic proximity Read ↗

Pharmacogenetics role in the safety of acenocoumarol therapy.Semantic proximity Read ↗

Pharmacogenomics of 4-hydroxycoumarin anticoagulants.Semantic proximity Read ↗

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.